



COUNTRY SUPPLEMENT
Pacific Capital UCITS Funds plc (THE "COMPANY")

ADDITIONAL INFORMATION FOR INVESTORS IN THE UNITED KINGDOM

DATED 10 July 2019

This Country Supplement forms part of and should be read in conjunction with the Prospectus of Pacific Capital UCITS Funds plc (the "Company") dated 5 July 2019 ("the Prospectus"). All capitalised terms contained herein shall have the same meaning in this Country Supplement as in the Prospectus unless otherwise indicated.

The Directors of the Company accept responsibility for the information contained in this Country Supplement and in the Prospectus. To the best of the knowledge and belief of the Directors (who have taken all reasonable care to ensure that such is the case) the information contained in this document is in accordance with the facts and does not omit anything likely to affect the import of such information. The Directors accept responsibility accordingly.

1. Name and address of the collective investment scheme:

Pacific Capital UCITS Funds plc, an ICVC "*investment company with variable capital*" was created under the laws of Ireland on 24 November 2014.

The Company is a self-managed ICVC.

2. United Kingdom Facilities Agent

The Company has appointed Pacific Capital Partners Limited, its principal place of business being 124 Sloane Street, London SW1X 9BW, UK as its UK Facilities Agent.

Investors can obtain information about the most recent prices and redemption facilities from the office of the UK Facilities Agent detailed above. Updated prices are also available under www.pacificam.co.uk and www.bloomberg.com.

Concerning the information regarding the subscription, redemption, transfer and conversion of shares in the Sub-Fund, please refer to the relevant Sections of the latest available Prospectus or in the supplement of the Sub-Fund.

UK resident investors should seek their own professional advice as to tax matters and other relevant considerations. Please note that investors making investments in the Company may not receive back their entire investment.

Although the Company is authorised by the Financial Conduct Authority for the purposes of distribution, potential and current investors in the UK are advised that the rules made under Financial Services and Market Act (FSMA) do not in general apply to the Company in relation to its investment business.

3. Information to investors

The following documents and/or information are available for inspection free of charge at the office of the UK Facilities Agent:

- a) The latest available prospectus and key investor information documents,
- b) The latest Memorandum and Articles of Association of the Company and any amendments thereto,
- c) The latest annual and semi-annual financial reports of the Company (if available),



d) The issue and redemption prices.

4. Written Complaints

Written complaints about any aspect of the service including the operations of the Company, or requests to obtain a copy of the complaints handling procedure can be addressed to the Facilities Agent Pacific Capital Partners Limited, 124 Sloane Street, London SW1X 9BW, UK for their further submission to the Company's head office.

5. Cancellation Rights

Please note that the investors have no rights of cancellation in respect of their holding.

6. Compensation Rights

Potential investors should be aware that Pacific Capital UCITS Funds plc is not subject to the rules and regulations made under FSMA for the protection of investors. Investors will not have any protection under the United Kingdom Financial Services Compensation Scheme.

7. UK Taxation

The foregoing is based on the Company's understanding of the law and practice currently in force in the United Kingdom and is subject to changes therein. It should not be taken as constituting legal or tax advice and, Investors should obtain information and, if necessary, should consult their professional advisers on the possible tax or other consequences of buying, holding, transferring or selling the units under the laws of their countries of origin citizenship, residence or domicile. Furthermore the content of this document is for information purposes only, it does not constitute any offer or promotion of sale nor does it make any reference to the suitability of investments referred to herein.